This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Background The effect of cardiac rehabilitation on functional recovery following a coronary event in the very elderly population is not well known. We intend to evaluate, as a primary objective, the impact of cardiac rehabilitation with both intense aerobic and resistance training on specific measured physical activities in a simulated home-setting laboratory, in the very old population. Our secondary objective is to evaluate the impact of cardiac rehabilitation on other on physical function indicators (measured physical performance tests and questionnaires) and body composition.Methods This is a prospective controlled clinical study. The study groups will include an active treatment group composed of 10 elderly patients aged over 75 years, living in the Burlington area, and a control group composed of 10 similar patients from remote areas of Vermont or upstate New York, where cardiac rehabilitation is not available. Participants will be recruited from Fletcher Allen Health Care while hospitalized for a coronary event, such as myocardial infarction, coronary revascularization (either coronary artery bypass surgery or percutaneous revascularization), or acute coronary syndrome. For the patients in the cardiac rehabilitation group, the exercise training will consist of 36 sessions of aerobic exercise and resistance training over a 4 months period (standard of care). Subjects in the control group will be managed as usual care by their personal cardiologist, who should recommend doing exercise in accordance with current guidelines for secondary prevention. Before and after the 4-months period patients will be tested with the Physical Functional Performance-10 (PFP-10). The result of the PFP-10 constitutes our primary end-point. This test has been validated in multiple clinical populations. It uses time, distance, and weight carried to evaluate physical function, based on the performance of 10 sequentially performed common household tasks. The 10 tasks are reported as a total score (0-100) averaging five separate physical domains. The domains are 1) upper-body strength, 2) lower-body strength, 3) upper-body flexibility, 4) balance and coordination, and 5) endurance. Physical function will also be measured by means of other tests requiring the participants to perform specific tasks; Short Physical Performance Battery (SPPB), peak oxygen consumption (peak VO2), and peak exercise capacity, single-repetition maximal lifts (1 RM), and 4 day step counts with pedometer. In addition, self reported physical function will be assessed by means of questionnaires; Medical Outcomes Study 36-Item Short-Form Survey (MOS SF-36and SF-36 Physical Function (SF-36 PF), Geriatric Depression Scale (GDS), Activities of Daily Living (ADLs) questionnaire, and CHAMPS physical activity questionnaire. A body composition analysis using body mass index (BMI) and Dual Energy X-Ray Absorptiometry (DEXA)-Scan will also be performed. With 20 participants we calculated that the present study will have a power of 99 % to detect a PFP-10 score improvement of 14 in the active treatment group, with a two-sided p-value of 0.05.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
General Clinical Research Centers Program (M01)
Project #
Application #
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Vermont & St Agric College
Schools of Medicine
United States
Zip Code
Scagnelli, Connor N; Howard, Diantha B; Bromberg, Mark B et al. (2018) Hydration measured by doubly labeled water in ALS and its effects on survival. Amyotroph Lateral Scler Frontotemporal Degener 19:220-231
Horne, Hisani N; Sherman, Mark E; Pfeiffer, Ruth M et al. (2016) Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease. Breast Cancer Res 18:24
Kien, C Lawrence; Matthews, Dwight E; Poynter, Matthew E et al. (2015) Increased palmitate intake: higher acylcarnitine concentrations without impaired progression of ?-oxidation. J Lipid Res 56:1795-807
Gierach, Gretchen L; Patel, Deesha A; Falk, Roni T et al. (2015) Relationship of serum estrogens and metabolites with area and volume mammographic densities. Horm Cancer 6:107-19
Albert, Kimberly; Pruessner, Jens; Newhouse, Paul (2015) Estradiol levels modulate brain activity and negative responses to psychosocial stress across the menstrual cycle. Psychoneuroendocrinology 59:14-24
Bodelon, Clara; Heaphy, Christopher M; Meeker, Alan K et al. (2015) Leukocyte telomere length and its association with mammographic density and proliferative diagnosis among women undergoing diagnostic image-guided breast biopsy. BMC Cancer 15:823
Morris, Erin A; Hale, Sarah A; Badger, Gary J et al. (2015) Pregnancy induces persistent changes in vascular compliance in primiparous women. Am J Obstet Gynecol 212:633.e1-6
Miller, Mark S; Bedrin, Nicholas G; Ades, Philip A et al. (2015) Molecular determinants of force production in human skeletal muscle fibers: effects of myosin isoform expression and cross-sectional area. Am J Physiol Cell Physiol 308:C473-84
Kien, C Lawrence; Bunn, Janice Y; Fukagawa, Naomi K et al. (2015) Lipidomic evidence that lowering the typical dietary palmitate to oleate ratio in humans decreases the leukocyte production of proinflammatory cytokines and muscle expression of redox-sensitive genes. J Nutr Biochem 26:1599-606
Wills, Anne-Marie; Hubbard, Jane; Macklin, Eric A et al. (2014) Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 383:2065-2072

Showing the most recent 10 out of 94 publications